Key Points
- Carbon Nano Technology Taiwan sold 46,000 shares of Ainos (NASDAQ:AIMD) on Jan. 28 at an average price of $2.17, a ~$99,820 transaction that reduced its holding by 4.44% to 989,925 shares, according to an SEC filing.
- Ainos is a small, volatile clinical‑stage biotech with a market capitalization of about $11.3 million, a negative recent quarterly EPS (−$0.64), and an average analyst rating of Sell.
- Institutional activity includes Two Sigma purchasing a new stake of 23,008 shares (~0.48% of the company) last quarter, valued at roughly $80,000.
Ainos, Inc. (NASDAQ:AIMD - Get Free Report) major shareholder Carbon Nano Technology Taiwan sold 46,000 shares of Ainos stock in a transaction that occurred on Wednesday, January 28th. The stock was sold at an average price of $2.17, for a total transaction of $99,820.00. Following the completion of the transaction, the insider directly owned 989,925 shares in the company, valued at $2,148,137.25. This represents a 4.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
Carbon Nano Technology Taiwan also recently made the following trade(s):
- On Friday, January 9th, Carbon Nano Technology Taiwan sold 431 shares of Ainos stock. The shares were sold at an average price of $1.86, for a total transaction of $801.66.
- On Thursday, January 8th, Carbon Nano Technology Taiwan sold 850 shares of Ainos stock. The stock was sold at an average price of $1.80, for a total transaction of $1,530.00.
Ainos Price Performance
NASDAQ AIMD opened at $2.35 on Friday. Ainos, Inc. has a 1 year low of $1.61 and a 1 year high of $4.50. The business's fifty day moving average is $1.99 and its two-hundred day moving average is $2.85. The stock has a market capitalization of $11.30 million, a P/E ratio of -0.59 and a beta of 2.45. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.67 and a current ratio of 2.96.
Ainos (NASDAQ:AIMD - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.64) earnings per share for the quarter. The firm had revenue of $0.00 million during the quarter.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Ainos in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of "Sell".
Read Our Latest Stock Analysis on AIMD
Institutional Trading of Ainos
An institutional investor recently bought a new position in Ainos stock. Two Sigma Investments LP purchased a new stake in shares of Ainos, Inc. (NASDAQ:AIMD - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 23,008 shares of the company's stock, valued at approximately $80,000. Two Sigma Investments LP owned approximately 0.48% of Ainos at the end of the most recent quarter.
About Ainos
(
Get Free Report)
Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company's proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.
The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
